7月23日 - ** 基因编辑公司Precision BioSciences DTIL.O股价盘前上涨10.1%至5.37美元
** 该公司表示， (link)，美国食品和药物管理局已授予其治疗杜氏肌营养不良症的实验性药物PBGENE-DMD "孤儿药 "标签(DMD)
** 美国食品和药物管理局授予孤儿药资格，以促进影响美国少于 20 万人的罕见疾病的药物开发。
** DMD 会导致骨骼肌和心肌无力，并随着时间的推移迅速恶化
** 预计在 2026 年获得 DMD 治疗的临床数据
** 截至上次收盘，股价累计上涨 27.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.